SEC Comment Letter 0000000000-23-000388 to BioAtla, Inc. (BCAB)
BioAtla, Inc.
Date: Jan. 13, 2023 · CIK: 0001826892 · Accession: 0000000000-23-000388
AI Filing Summary & Sentiment
File numbers found in text: 333-269148
Letter
United States securities and exchange commission logo January 13, 2023 Jay Short Co-Founder, Chief Executive Officer and Chairman BioAtla, Inc. 11085 Torreyana Road San Diego, California, 92121 Re:BioAtla, Inc. Registration Statement on Form S-3 Filed on January 6, 2023 File No. 333-269148 Dear Jay Short: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nikki Fang, Esq.
Show Raw Text
United States securities and exchange commission logo
January 13, 2023
Jay Short
Co-Founder, Chief Executive Officer and Chairman
BioAtla, Inc.
11085 Torreyana Road
San Diego, California, 92121
Re:BioAtla, Inc.
Registration Statement on Form S-3
Filed on January 6, 2023
File No. 333-269148
Dear Jay Short:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nikki Fang, Esq.